NeoPharm CO., LTD. (KOSDAQ: 092730)

Market Cap	201.62B
Revenue (ttm)	107.86B
Net Income (ttm)	22.93B
Shares Out	15.64M
EPS (ttm)	1,465.96
PE Ratio	8.79
Forward PE	7.50
Dividend	375.00 (2.87%)
Ex-Dividend Date	n/a

Volume	19,060
Open	13,120
Previous Close	13,010
Day's Range	12,820 - 13,480
52-Week Range	12,360 - 34,300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 172
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092730

Financial Performance

In 2023, NeoPharm CO., LTD.'s revenue was 97.10 billion, an increase of 14.20% compared to the previous year's 85.03 billion. Earnings were 23.21 billion, an increase of 36.33%.